𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetic and clinical evaluation of liquid L-dopa/carbidopa in Parkinson's disease

✍ Scribed by J Marriott; B Bryant; P Kempster; M Shif; M.McD Lewis; M Horne

Book ID
117685588
Publisher
Elsevier Science
Year
1998
Tongue
English
Weight
387 KB
Volume
5
Category
Article
ISSN
0967-5868

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparative study of selegiline plus L-d
Comparative study of selegiline plus L-dopa–carbidopa versus L-dopa–carbidopa alone in the treatment of parkinson's disease
✍ Timothy Brannan; Dr. Melvin D. Yahr 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB 👁 1 views

The long-term effect of selegiline (L-deprenyl) in the treatment of Parkinson's disease has not been clearly delineated. We report on a group of patients whose treatment was initiated with selegiline (n = 43) and then subsequently included L-dopa-carbidopa (Sinemet) and in whom an extended period o

EFFECTS OF L-DOPA IN PARKINSON'S DISEASE
EFFECTS OF L-DOPA IN PARKINSON'S DISEASE
✍ Godwin-Austen, R.B; Frears, C.C; Tomlinson, E.B; Kok, H.W.L 📂 Article 📅 1969 🏛 The Lancet 🌐 English ⚖ 570 KB
Comparison of standard carbidopa–levodop
Comparison of standard carbidopa–levodopa and sustained-release carbidopa–levodopa in parkinson's disease: Pharmacokinetic and quality-of-life measures
✍ Dr. Rajesh Pahwa; Kelly Lyons; Desni McGuire; Paul Silverstein; Felix Zwiebel; M 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB

## Abstract We compared clinical, pharmacokinetic, and quality‐of‐life measures in patients with Parkinson's disease (PD) who were on standard carbidopa‐levodopa (Std‐L) and after conversion to sustained‐release carbidopa‐levodopa 50/200 (L‐CR). A total of 20 PD patients with motor fluctuations par